{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:58:06Z","timestamp":1793228286242,"version":"4.5.0"},"reference-count":276,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008425","name":"Government of Galicia Department of Education Science Universities and Professional Training","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/01410"],"award-info":[{"award-number":["PI24\/01410"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010568","name":"Secretaria Xeral de Investigaci\u00f3n e Desenvolvemento, Xunta de Galicia","doi-asserted-by":"publisher","award":["ED481A-2021\/364"],"award-info":[{"award-number":["ED481A-2021\/364"]}],"id":[{"id":"10.13039\/501100010568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.addr.2025.115638","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:23:26Z","timestamp":1750058606000},"page":"115638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0700-6013","authenticated-orcid":false,"given":"Immacolata","family":"Maietta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-4825","authenticated-orcid":false,"given":"\u00c1frica","family":"Gonz\u00e1lez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8963-6547","authenticated-orcid":false,"given":"Rosana","family":"Sim\u00f3n-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115638_b0005","unstructured":"Pancreatic Cancer Action Network. What is pancreatic cancer? 2025. https:\/\/pancan.org\/facing-pancreatic-cancer\/about-pancreatic-cancer\/what-is-pancreatic-cancer\/ (accessed May 27, 2025)."},{"key":"10.1016\/j.addr.2025.115638_b0010","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2025.115638_b0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0020","unstructured":"International Agency for Research on Cancer (IARC). Global Cancer Observatory 2025. https:\/\/gco.iarc.who.int\/en (accessed May 27, 2025)."},{"key":"10.1016\/j.addr.2025.115638_b0025","unstructured":"International Agency for Research on Cancer (IARC). Cancer Incidence in 5 Continents 2025. https:\/\/ci5.iarc.fr\/ (accessed May 27, 2025)."},{"key":"10.1016\/j.addr.2025.115638_b0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2024-001544","article-title":"Current and projected incidence rates of pancreatic cancer in 43 countries: an analysis of the cancer incidence in five continents database","volume":"12","author":"Shou","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"10.1016\/j.addr.2025.115638_b0035","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2025.115638_b0040","unstructured":"American Cancer Society. Survival rates for pancreatic cancer 2025. https:\/\/www.cancer.org\/cancer\/types\/pancreatic-cancer\/detection-diagnosis-staging\/survival-rates.html (accessed May 27, 2025)."},{"key":"10.1016\/j.addr.2025.115638_b0045","unstructured":"National Cancer Institute (NIH). Cancer stat facts: pancreatic cancer 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html (accessed May 27, 2025)."},{"key":"10.1016\/j.addr.2025.115638_b0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis","volume":"520","author":"Cai","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2025.115638_b0060","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/s41379-020-0629-6","article-title":"The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go","volume":"33","author":"Thompson","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.addr.2025.115638_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040799","article-title":"Targeted therapies for pancreatic cancer: overview of current treatments and new opportunities for personalized oncology","volume":"13","author":"Leroux","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0070","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2025.115638_b0075","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211056179","article-title":"Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial","volume":"13","author":"Huh","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0080","unstructured":"Cancer Research UK. Survival for pancreatic cancer 2025. https:\/\/www.cancerresearchuk.org\/about-cancer\/pancreatic-cancer\/survival (accessed May 27, 2025)."},{"key":"10.1016\/j.addr.2025.115638_b0085","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2217\/epi-2015-0016","article-title":"The promise of epigenomic therapeutics in pancreatic cancer","volume":"8","author":"Lomberk","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.addr.2025.115638_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers10050128","article-title":"Targeting epigenetic aberrations in pancreatic cancer, a new path to improve patient outcomes?","volume":"10","author":"Paradise","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0095","doi-asserted-by":"crossref","DOI":"10.1159\/000477773","article-title":"tumor heterogeneity in pancreatic adenocarcinoma","volume":"85","author":"Cros","year":"2018","journal-title":"Pathobiology"},{"key":"10.1016\/j.addr.2025.115638_b0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrgastro.2017.12","article-title":"Acinar cell plasticity and development of pancreatic ductal adenocarcinoma","volume":"14","author":"Storz","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2025.115638_b0105","article-title":"The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2025.115638_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2021.795251","article-title":"Cell lineage infidelity in PDAC progression and therapy resistance","volume":"9","author":"Malinova","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2025.115638_b0115","article-title":"Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype","author":"Liffers","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115638_b0120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.275776.115","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"30","author":"Ying","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2025.115638_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5040065","article-title":"Pancreatic Cancer: molecular characterization, clonal evolution and cancer stem cells","volume":"5","author":"Pelosi","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2025.115638_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9124128","article-title":"Molecular and metabolic subtypes correspondence for pancreatic ductal adenocarcinoma classification","volume":"9","author":"Espiau-Romera","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2025.115638_b0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.addr.2025.115638_b0140","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00423-024-03506-6","article-title":"Histological variants of pancreatic ductal adenocarcinoma: a survival analysis","volume":"409","author":"Bengtsson","year":"2024","journal-title":"Langenbecks Arch. Surg."},{"key":"10.1016\/j.addr.2025.115638_b0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115638_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21197307","article-title":"The immune microenvironment in pancreatic cancer","volume":"21","author":"Huber","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0155","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","article-title":"Microenvironmental determinants of pancreatic cancer","volume":"100","author":"Hessmann","year":"2020","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.addr.2025.115638_b0160","article-title":"The Extracellular Matrix: a key accomplice of cancer stem cell migration, metastasis formation and drug resistance in PDAC","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90077-x","article-title":"ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis","volume":"11","author":"Islam","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115638_b0170","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1039\/D0BM00916D","article-title":"Co-inhibition of the TGF-\u03b2 pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy","volume":"12","author":"Sarantis","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.addr.2025.115638_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and cancer: a strained relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0185","doi-asserted-by":"crossref","first-page":"7956","DOI":"10.3748\/wjg.v27.i46.7956","article-title":"T cells in pancreatic cancer stroma","volume":"27","author":"Goulart","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2025.115638_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327855","article-title":"IL-17A-producing CD8 + T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts","volume":"72","author":"Picard","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115638_b0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111627","article-title":"Myeloid-derived suppressor cells and pancreatic cancer: implications in novel therapeutic approaches","volume":"11","author":"Thyagarajan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41419-018-0486-0","article-title":"Tumor-associated macrophages promote progression and the Warburg effect via CCL18\/NF-kB\/VCAM-1 pathway in pancreatic ductal adenocarcinoma","volume":"9","author":"Ye","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2025.115638_b0210","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41467-019-09416-2","article-title":"Specialized dendritic cells induce tumor-promoting IL-10+IL-17+ FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma","volume":"10","author":"Barilla","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115638_b0215","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.addr.2025.115638_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1152551","article-title":"Pancreatic cancer: emerging field of regulatory B-cell-targeted immunotherapies","volume":"14","author":"Senturk","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115638_b0225","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1042\/CS20191211","article-title":"Emerging roles for the IL-6 family of cytokines in pancreatic cancer","volume":"134","author":"van Duijneveldt","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.addr.2025.115638_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152210","article-title":"CCR4+ monocytic myeloid-derived suppressor cells are associated with the increased epithelial-mesenchymal transition in pancreatic adenocarcinoma patients","volume":"227","author":"Sharma","year":"2022","journal-title":"Immunobiology"},{"key":"10.1016\/j.addr.2025.115638_b0235","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.semcancer.2022.03.021","article-title":"Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment","volume":"86","author":"Bhatia","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.addr.2025.115638_b0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cca.2012.12.025","article-title":"Molecular markers in pancreatic cancer diagnosis","volume":"418","author":"Herreros-Villanueva","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.addr.2025.115638_b0245","article-title":"Biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0250","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.3748\/wjg.v27.i26.4045","article-title":"Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?","volume":"27","author":"O\u2019Neill","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2025.115638_b0255","first-page":"11683","article-title":"Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.addr.2025.115638_b0260","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1111\/cas.13712","article-title":"Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer","volume":"109","author":"Dong","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2025.115638_b0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41374-020-00490-5","article-title":"Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer","volume":"101","author":"Singh","year":"2021","journal-title":"Lab. Invest."},{"key":"10.1016\/j.addr.2025.115638_b0270","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/carcin\/bgz122","article-title":"Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis","volume":"41","author":"Matsuura","year":"2020","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2025.115638_b0275","doi-asserted-by":"crossref","DOI":"10.1038\/srep08535","article-title":"Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines","volume":"5","author":"Stolze","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2025.115638_b0280","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.addr.2025.115638_b0285","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0290","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025631118","article-title":"TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment","volume":"118","author":"Maddalena","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2025.115638_b0295","first-page":"1115","article-title":"TP53 Mutational status-based genomic signature for prognosis and predicting therapeutic response in pancreatic cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2025.115638_b0300","first-page":"1","article-title":"CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition","volume":"19","author":"Chan","year":"2021","journal-title":"Hereditary Cancer Clin. Pract."},{"key":"10.1016\/j.addr.2025.115638_b0305","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2147\/OTT.S232464","article-title":"Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.addr.2025.115638_b0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.278","article-title":"The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma","volume":"37","author":"Doyle","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0315","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/cancers14040973","article-title":"The role of SMAD4 inactivation in epithelial & mesenchymal plasticity of pancreatic ductal adenocarcinoma: the missing link?","volume":"14","author":"Racu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2025.115638_b0320","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fonc.2022.806963","article-title":"Loss of SMAD4 is associated with poor tumor immunogenicity and reduced PD-L1 expression in pancreatic cancer","volume":"12","author":"Principe","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0325","doi-asserted-by":"crossref","first-page":"C115","DOI":"10.1158\/1538-7445.PANCA2023-C115","article-title":"Abstract C115: genomic evolution of pancreatic cancer at single-cell resolution","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0330","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/1940-6207.CAPR-21-0161","article-title":"EUS-based pancreatic cancer surveillance in BRCA1\/BRCA2\/PALB2\/ATM carriers without a family history of pancreatic cancer","volume":"14","author":"Katona","year":"2021","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.addr.2025.115638_b0335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040897","article-title":"Precision medicine for BRCA\/PALB2-mutated pancreatic cancer and emerging strategies to improve therapeutic responses to PARP inhibition","volume":"14","author":"Principe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0340","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41416-021-01469-9","article-title":"BRCA-mutant pancreatic ductal adenocarcinoma","volume":"125","author":"Lai","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0345","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000942","article-title":"Molecular characteristics of BRCA1\/2 and PALB2 mutations in pancreatic ductal adenocarcinoma","volume":"5","author":"Seeber","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.addr.2025.115638_b0350","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature19823","article-title":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","volume":"538","author":"Notta","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115638_b0355","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","article-title":"Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications","volume":"42","author":"Hu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2025.115638_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18040779","article-title":"Molecular drivers of pancreatic cancer pathogenesis: Looking inward to move forward","volume":"18","author":"Khan","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14235926","article-title":"Epigenetics in pancreatic ductal adenocarcinoma: impact on biology and utilization in diagnostics and treatment","volume":"14","author":"Elrakaybi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0370","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.addr.2025.115638_b0375","doi-asserted-by":"crossref","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.hbpd.2020.03.010","article-title":"Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions","volume":"19","author":"Bararia","year":"2020","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.addr.2025.115638_b0385","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-020-00526-4","article-title":"DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications","volume":"43","author":"Wong","year":"2020","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"10.1016\/j.addr.2025.115638_b0390","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.2147\/CMAR.S201610","article-title":"DNMT3a promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer","volume":"11","author":"Jing","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.addr.2025.115638_b0395","article-title":"A DNA-methylation-driven genes based prognostic signature reveals immune microenvironment in pancreatic cancer","volume":"13","author":"Xiao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115638_b0400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115638_b0405","article-title":"Histone modifications represent a key epigenetic feature of epithelial-to-mesenchyme transition in pancreatic cancer","volume":"24","author":"Xu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0410","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12885-018-4061-y","article-title":"Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells","volume":"18","author":"Lu","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0415","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1053\/j.gastro.2019.08.018","article-title":"The histone demethylase KDM3A, increased in human pancreatic tumors, regulates expression of DCLK1 and promotes tumorigenesis in mice","volume":"157","author":"Dandawate","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2025.115638_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-023-01813-y","article-title":"Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma","volume":"22","author":"Gautam","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216706","article-title":"EZH2-mediated development of therapeutic resistance in cancer","volume":"586","author":"Kaur","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2025.115638_b0430","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211812","article-title":"The paradigm of drug resistance in cancer: an epigenetic perspective","volume":"42","author":"Adhikari","year":"2022","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.addr.2025.115638_b0435","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cmet.2024.03.015","article-title":"QDPR deficiency drives immune suppression in pancreatic cancer","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.addr.2025.115638_b0440","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1158\/0008-5472.CAN-20-0672","article-title":"EZH2 regulates pancreatic cancer subtype identity and tumor progression via transcriptional repression of GATA6","volume":"80","author":"Patil","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0445","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.3748\/wjg.v27.i36.6004","article-title":"Histone methylation in pancreatic cancer and its clinical implications","volume":"27","author":"Liu","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.addr.2025.115638_b0450","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s43018-023-00553-8","article-title":"EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance","volume":"4","author":"Chibaya","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0455","first-page":"1","article-title":"The cancer driver genes IDH1\/2, JARID1C\/ KDM5C, and UTX\/KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism","volume":"51","author":"Chang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.addr.2025.115638_b0460","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202050967","article-title":"Histone acetyltransferase 1 is a succinyltransferase for histones and non-histones and promotes tumorigenesis","volume":"22","author":"Yang","year":"2021","journal-title":"EMBO Rep."},{"key":"10.1016\/j.addr.2025.115638_b0465","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tips.2024.01.010","article-title":"Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy","volume":"45","author":"White","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0470","first-page":"1","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Trans. Target. Ther."},{"key":"10.1016\/j.addr.2025.115638_b0475","first-page":"2379","article-title":"Regulation of histone deacetylase activities and functions by phosphorylation and dephosphorylation","volume":"3","author":"Seto","year":"2009","journal-title":"Handbook of cell signaling, Second Edition"},{"key":"10.1016\/j.addr.2025.115638_b0480","article-title":"Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer","volume":"1877","author":"Xiang","year":"2022","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2025.115638_b0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02807-4","article-title":"HDACs\/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53","volume":"22","author":"Mao","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.addr.2025.115638_b0490","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031631","article-title":"Inhibition of the RAF\/MEK\/ERK signaling cascade in pancreatic cancer: recent advances and future perspectives","volume":"25","author":"Adamopoulos","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0495","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710132","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects","volume":"23","author":"Stanciu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0500","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/0008-5472.CAN-20-3209","article-title":"HDAC2 facilitates pancreatic cancer metastasis","volume":"82","author":"Krau\u00df","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0505","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1245\/s10434-016-5171-x","article-title":"Phosphorylated histone H3 (PHH3) is a superior proliferation marker for prognosis of pancreatic neuroendocrine tumors","volume":"23","author":"Villani","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0510","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrm.2016.58","article-title":"Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers","volume":"17","author":"Schwertman","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2025.115638_b0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.09.001","article-title":"Dysregulation of ubiquitin ligases in cancer","volume":"23","author":"Qi","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.addr.2025.115638_b0520","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115638_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217117","article-title":"Histone lactylation dynamics: Unlocking the triad of metabolism, epigenetics, and immune regulation in metastatic cascade of pancreatic cancer","volume":"598","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.addr.2025.115638_b0530","doi-asserted-by":"crossref","DOI":"10.2217\/epi-2022-0177","article-title":"Role of epigenetics in pancreatic ductal adenocarcinoma","author":"Pandey","year":"2023","journal-title":"Epigenomics"},{"key":"10.1016\/j.addr.2025.115638_b0535","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13072-019-0264-y","article-title":"The BAF complex in development and disease","volume":"12","author":"Alfert","year":"2019","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.addr.2025.115638_b0540","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115638_b0545","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061518","article-title":"Targeting BPTF sensitizes pancreatic ductal adenocarcinoma to chemotherapy by repressing ABC-transporters and impairing multidrug resistance (MDR)","volume":"14","author":"Mu\u00f1oz Velasco","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0550","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1038\/onc.2013.488","article-title":"Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer","volume":"33","author":"Hall","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2025.115638_b0555","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41419-019-1424-5","article-title":"MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity","volume":"10","author":"Si","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2025.115638_b0560","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121859","article-title":"The emerging roles of ATP-dependent chromatin remodeling complexes in pancreatic cancer","volume":"11","author":"Hasan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0565","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3389\/fonc.2020.00309","article-title":"Non-coding RNAs in pancreatic ductal adenocarcinoma","volume":"10","author":"Gong","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110813","article-title":"SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine","volume":"39","author":"Wang","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2025.115638_b0575","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/17425255.2021.1887139","article-title":"The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer","volume":"17","author":"Wang","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.addr.2025.115638_b0580","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.717890","article-title":"Long non-coding RNAs in epithelial-mesenchymal transition of pancreatic cancer","volume":"8","author":"Takahashi","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.addr.2025.115638_b0585","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.7150\/thno.40566","article-title":"A miR-146a-5p\/TRAF6\/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance","volume":"10","author":"Meng","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2025.115638_b0590","first-page":"5668","article-title":"Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients","volume":"12","author":"Ali","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0595","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111665","article-title":"LncRNAs: novel biomarkers for pancreatic cancer","volume":"11","author":"Ghafouri-Fard","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.addr.2025.115638_b0600","doi-asserted-by":"crossref","first-page":"84928","DOI":"10.18632\/oncotarget.20863","article-title":"PDAC-derived exosomes enrich the microenvironment in MDSCs in a SMAD4-dependent manner through a new calcium related axis","volume":"8","author":"Basso","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2025.115638_b0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.01013","article-title":"The interaction between long non-coding RNA HULC and MicroRNA-622 via transfer by extracellular vesicles regulates cell invasion and migration in human pancreatic cancer","volume":"10","author":"Takahashi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0610","doi-asserted-by":"crossref","DOI":"10.3390\/genes11010014","article-title":"Cell-free DNA methylation: the new frontiers of pancreatic cancer biomarkers\u2019 discovery","volume":"11","author":"Brancaccio","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0615","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/MPA.0000000000001919","article-title":"Methylation-based cell-free DNA signature for early detection of pancreatic cancer","volume":"50","author":"Ying","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.addr.2025.115638_b0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-020-00898-2","article-title":"Integrated epigenetic biomarkers in circulating cell-free DNA as a robust classifier for pancreatic cancer","volume":"12","author":"Cao","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.addr.2025.115638_b0625","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pan.2021.05.003","article-title":"Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma \u2013 An external validation study","volume":"21","author":"Henriksen","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.addr.2025.115638_b0630","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MPA.0b013e318221c903","article-title":"The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer","volume":"41","author":"Park","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.addr.2025.115638_b0635","article-title":"Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin","volume":"11","author":"Eissa","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.addr.2025.115638_b0640","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3389\/fonc.2021.688377","article-title":"The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy","volume":"11","author":"Principe","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0645","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33916","article-title":"Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma","volume":"150","author":"de Jong","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0650","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.2286","article-title":"Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma","volume":"155","author":"Perri","year":"2020","journal-title":"JAMA Surg."},{"key":"10.1016\/j.addr.2025.115638_b0655","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2012.782","article-title":"Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer","volume":"4","author":"Kim","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.addr.2025.115638_b0660","article-title":"Cisplatin, fluorouracil in bolus injection, and leucovorin in first-line therapy for advanced gastric cancer as an alternative to protocols with infusional fluorouracil","volume":"2019","author":"Coelho","year":"2019","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.addr.2025.115638_b0665","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246223","article-title":"Emerging role of targeted therapy in metastatic pancreatic adenocarcinoma","volume":"14","author":"Huffman","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0670","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","article-title":"First approval","volume":"85","author":"Zenocutuzumab","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2025.115638_b0675","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0680","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0685","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/tgh.2020.04.03","article-title":"Pancreatic cancer and immune checkpoint inhibitors-still a long way to go","volume":"6","author":"Bian","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.addr.2025.115638_b0690","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3390\/curroncol30040293","article-title":"Pancreatic ductal adenocarcinoma and immune checkpoint inhibitors: the gray curtain of immunotherapy and spikes of lights","volume":"30","author":"Balsano","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0695","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.addr.2025.115638_b0700","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2025.115638_b0705","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1200\/JCO.2024.42.16_suppl.4133","article-title":"OPTIMIZE-1 primary analysis: safety, efficacy and biomarker results of a phase 1b\/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"42","author":"Van Laethem","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1153724","article-title":"Immunization with nanovaccines containing mutated K-Ras peptides and imiquimod aggravates heterotopic pancreatic cancer induced in mice","volume":"14","author":"Mart\u00ednez-P\u00e9rez","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115638_b0715","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic cell-based cancer vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2025.115638_b0720","first-page":"491","article-title":"Engineered tumor cell-derived vaccines against cancer: the art of combating poison with poison","volume":"22","author":"Zhang","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.addr.2025.115638_b0725","unstructured":"DC Vaccine in Pancreatic Cancer \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03592888 (accessed August 31, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b0730","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115638_b0735","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","article-title":"FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2025.115638_b0740","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1038\/s41467-021-27349-7","article-title":"Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance","volume":"12","author":"Deng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115638_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114716","article-title":"Vactosertib, TGF-\u03b2 receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer","volume":"162","author":"Lee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2025.115638_b0750","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1097\/MPA.0000000000002277","article-title":"Advancements in preclinical models of pancreatic cancer","volume":"53","author":"Salu","year":"2024","journal-title":"Pancreas"},{"key":"10.1016\/j.addr.2025.115638_b0755","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030890","article-title":"Pancreatic cancer organoids: an emerging platform for precision medicine?","volume":"11","author":"Sereti","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2025.115638_b0760","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5306\/wjco.v2.i5.195","article-title":"Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations","volume":"2","author":"Ijichi","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0765","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2025.115638_b0770","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MPA.0000000000001195","article-title":"Tenascin C, fibronectin, and tumor-stroma ratio in pancreatic ductal adenocarcinoma","volume":"48","author":"Lepp\u00e4nen","year":"2019","journal-title":"Pancreas"},{"key":"10.1016\/j.addr.2025.115638_b0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114357","article-title":"Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment","volume":"187","author":"Tarannum","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115638_b0780","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102033","article-title":"Nanoparticle-based therapeutic strategies for enhanced pancreatic ductal adenocarcinoma immunotherapy","volume":"14","author":"Hou","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115638_b0785","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jconrel.2020.02.040","article-title":"Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy","volume":"321","author":"Yu","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115638_b0790","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184504","article-title":"Chemoresistance in pancreatic cancer","volume":"20","author":"Zeng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0795","doi-asserted-by":"crossref","unstructured":"M A, IP G. Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel) 2017;9. doi: 10.3390\/CANCERS9110157.","DOI":"10.3390\/cancers9110157"},{"key":"10.1016\/j.addr.2025.115638_b0800","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","article-title":"Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL\u2013specific degrader DT2216","volume":"21","author":"Thummuri","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2025.115638_b0805","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174434","article-title":"Targeting PI3K pathway in pancreatic ductal adenocarcinoma: rationale and progress","volume":"13","author":"Mehra","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b0810","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/carcin\/bgw093","article-title":"TGF-\u03b2-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3","volume":"37","author":"Hesler","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.addr.2025.115638_b0815","article-title":"Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pa","volume":"12","author":"Lu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0820","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.addr.2025.115638_b0825","unstructured":"A study of penpulimab and anlotinib plus nab-paclitaxel and gemcitabine for metastatic pancreatic cancer. \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05493995?term=gemcitabine&recrs=a&cond=Pancreas+Cancer&draw=2&rank=12 (accessed April 12, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b0830","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4251\/wjgo.v14.i7.1252","article-title":"Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma","volume":"14","author":"Wang","year":"2022","journal-title":"World J. Gastrointest Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0835","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115638_b0840","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40265-020-01304-0","article-title":"New treatment strategies for metastatic pancreatic ductal adenocarcinoma","volume":"80","author":"Singh","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2025.115638_b0845","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18050909","article-title":"Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis","volume":"18","author":"Chiramel","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b0850","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4195","article-title":"Phase Ib\/IIa trial of CEND\u20101 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX)","volume":"40","author":"Kasi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0855","doi-asserted-by":"crossref","first-page":"240","DOI":"10.14740\/jmc3918","article-title":"Survival benefit of pembrolizumab for patients with pancreatic adenocarcinoma: a case series","volume":"13","author":"Zhao","year":"2022","journal-title":"J Med Cases"},{"key":"10.1016\/j.addr.2025.115638_b0860","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2020.38.4_suppl.754","article-title":"Exceptional responses to ipilimumab\/nivolumab (ipi\/nivo) in patients (pts) with refractory pancreatic ductal adenocarcinoma (PDAC) and germline BRCA or RAD51 mutations","volume":"38","author":"Terrero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0865","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","article-title":"Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib\/II umbrella randomized study platform","volume":"28","author":"Ko","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.addr.2025.115638_b0870","article-title":"Nano-drug delivery system for pancreatic cancer: a visualization and bibliometric analysis","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2025.115638_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101662","article-title":"A novel 3DNA\u00ae nanocarrier effectively delivers payloads to pancreatic tumors","volume":"32","author":"McCarthy","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0880","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.omto.2023.08.008","article-title":"JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis","volume":"30","author":"Cui","year":"2023","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0885","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41598-023-27825-8","article-title":"Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors","volume":"13","author":"Sakamoto","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115638_b0890","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cac2.12313","article-title":"Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials","volume":"42","author":"Xu","year":"2022","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.addr.2025.115638_b0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115179","article-title":"Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival","volume":"165","author":"Urbanova","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2025.115638_b0900","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-020-01151-3","article-title":"Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma","volume":"19","author":"Fan","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0905","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/371087","article-title":"Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I\/II report","volume":"2014","author":"Fan","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.addr.2025.115638_b0910","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/bs.acr.2021.03.007","article-title":"DNA methylation inhibitors: retrospective and perspective view","volume":"152","author":"Uddin","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0915","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1072651","article-title":"Recent progress in DNA methyltransferase inhibitors as anticancer agents","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2025.115638_b0920","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00538","article-title":"5-Azacytidine potentiates anti-tumor immunity in a model of pancreatic ductal adenocarcinoma","volume":"11","author":"Ebelt","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115638_b0925","first-page":"3047","article-title":"A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer","volume":"10","author":"Sohal","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0930","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004495","article-title":"Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors","volume":"10","author":"Papadatos-Pastos","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0935","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","article-title":"DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer","volume":"9","author":"Luo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115638_b0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0199130","article-title":"A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent","volume":"13","author":"Thakar","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2025.115638_b0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112660","article-title":"In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells","volume":"405","author":"Patki","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.addr.2025.115638_b0950","doi-asserted-by":"crossref","first-page":"8486","DOI":"10.1021\/acs.jmedchem.1c00420","article-title":"Development of HDAC inhibitors exhibiting therapeutic potential in T-cell prolymphocytic leukemia","volume":"64","author":"Toutah","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2025.115638_b0955","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/cas.13700","article-title":"Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer","volume":"109","author":"Shinke","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.addr.2025.115638_b0960","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/jco.2008.26.15_suppl.2567","article-title":"A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors","volume":"26","author":"Doss","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b0965","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1007\/s13277-015-4216-2","article-title":"SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin","volume":"37","author":"Park","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.addr.2025.115638_b0970","unstructured":"NPI-0052 and vorinostat in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00667082 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-019-0681-6","article-title":"Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status","volume":"11","author":"Chao","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.addr.2025.115638_b0980","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40487-016-0023-1","article-title":"Panobinostat as pan-deacetylase inhibitor for the treatment of pancreatic cancer: recent progress and future prospects","volume":"4","author":"Singh","year":"2016","journal-title":"Oncol Ther"},{"key":"10.1016\/j.addr.2025.115638_b0985","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/1471-2407-12-226","article-title":"Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer","volume":"12","author":"Dovzhanskiy","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115638_b0990","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-019-1160-9","article-title":"Valproic acid exhibits anti-tumor activity selectively against EGFR\/ErbB2\/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b0995","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13046-022-02295-4","article-title":"HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation","volume":"41","author":"Roca","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b1000","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-018-0634-5","article-title":"Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer","volume":"37","author":"Ikeda","year":"2019","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.addr.2025.115638_b1005","article-title":"Phase Ib Study of the histone deacetylase 6 inhibitor citarinostat in combination with paclitaxel in patients with advanced solid tumors","volume":"11","author":"Gordon","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b1010","article-title":"Class I and Class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2025.115638_b1015","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.31557\/APJCP.2020.21.7.2131","article-title":"Effect of Zebularine in comparison to and in combination with trichostatin A on CIP\/KIP Family (p21Cip1\/Waf1\/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene expression","volume":"21","author":"Sanaei","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.addr.2025.115638_b1020","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070824","article-title":"synergistic antitumoral effect of epigenetic inhibitors and gemcitabine in pancreatic cancer cells","volume":"15","author":"Maietta","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.addr.2025.115638_b1025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064566","article-title":"Three-dimensional collagen i promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression","volume":"8","author":"Dangi-Garimella","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2025.115638_b1030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejmech.2019.05.078","article-title":"Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism","volume":"178","author":"Huang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2025.115638_b1035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ebiom.2019.05.035","article-title":"The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors","volume":"44","author":"Miller","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2025.115638_b1040","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b1045","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/ refractory solid tumors","volume":"25","author":"Piha-Paul","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b1050","doi-asserted-by":"crossref","first-page":"18734","DOI":"10.18632\/oncotarget.24648","article-title":"BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC","volume":"9","author":"Jauset","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.addr.2025.115638_b1055","doi-asserted-by":"crossref","first-page":"E2721","DOI":"10.1073\/pnas.1406722111","article-title":"BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma","volume":"111","author":"Bhadury","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2025.115638_b1060","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116764119","article-title":"XP-524 is a dual-BET\/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2025.115638_b1065","first-page":"2389","article-title":"Histone methylation: chemically inert but chromatin dynamic","volume":"3","author":"Whetstine","year":"2009","journal-title":"Handbook of cell signaling, Second Edition"},{"key":"10.1016\/j.addr.2025.115638_b1070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gutjnl-2016-312539","article-title":"Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?","volume":"66","author":"Hessmann","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115638_b1075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b1080","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7150\/ijbs.64752","article-title":"SOX8 affects tumoral SPARC expression by regulating EZH2 to attenuate effectiveness of albumin-bound paclitaxel in PDAC","volume":"18","author":"Yuan","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b1085","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ccell.2020.04.014","article-title":"SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy","volume":"37","author":"Wang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115638_b1090","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.addr.2025.115638_b1095","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2025.115638_b1100","unstructured":"ORIOn-E: a study evaluating CPI-1205 in patients with advanced solid tumors \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03525795 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115440","article-title":"NSD3: Advances in cancer therapeutic potential and inhibitors research","volume":"256","author":"Xiu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2025.115638_b1110","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114558","article-title":"MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression","volume":"42","author":"Sun","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2025.115638_b1115","first-page":"1","article-title":"Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival","volume":"3","author":"Rozengurt","year":"2018","journal-title":"Signal Trans. Target. Ther."},{"key":"10.1016\/j.addr.2025.115638_b1120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133102","article-title":"Combined inhibition of FOSL-1 and YAP using siRNA-lipoplexes reduces the growth of pancreatic tumor","volume":"14","author":"Diego-Gonz\u00e1lez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b1125","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-023-10160-9","article-title":"The emerging roles of histone demethylases in cancers","author":"Tong","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.addr.2025.115638_b1130","article-title":"JIB-04, a pan-inhibitor of histone demethylases, targets histone-lysine-demethylase-dependent AKT pathway, leading to cell cycle arrest and inhibition of cancer stem-like cell properties in hepatocellular carcinoma cells","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115638_b1135","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/gutjnl-2020-321316","article-title":"Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4\u03b1 and SIX1\/4","volume":"70","author":"Camolotto","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.addr.2025.115638_b1140","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302037","article-title":"EBF2 links KMT2D\u2010mediated H3K4me1 to suppress pancreatic cancer progression via upregulating KLLN","volume":"11","author":"Yao","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2025.115638_b1145","unstructured":"Vorinostat and capecitabine in treating patients with metastatic or unresectable solid tumors \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00121277?term=vorinostat&cond=Solid+Tumor&draw=2&rank=2 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.radonc.2016.04.013","article-title":"Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer","volume":"119","author":"Chan","year":"2016","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b1155","unstructured":"Vorinostat and gemcitabine in treating patients with metastatic or unresectable solid tumors \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00243100?term=vorinostat&cond=Solid+Tumor&draw=2&rank=10 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1160","unstructured":"Vorinostat, paclitaxel, and carboplatin in treating patients with advanced or refractory solid tumors \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00287937?term=vorinostat&cond=Solid+Tumor&draw=2&rank=9 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1165","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/ijc.34144","article-title":"A phase I\/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma","volume":"151","author":"Jo","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2025.115638_b1170","unstructured":"A study of ivaltinostat plus capecitabine or capecitabine in metastatic pancreatic adenocarcinoma \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05249101?term=Ivaltinostat&draw=2&rank=1 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1175","unstructured":"ACY 241 in combination with paclitaxel in patients with advanced solid tumors \u2013 full text view \u2013 clinicaltrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02551185 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1180","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-CT136","article-title":"Phase Ib study of decitabine in combination with gemcitabine in treatment of refractory pancreatic adenocarcinoma and advanced soft tissue or bone sarcomas","volume":"78","author":"Abushahin","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b1185","unstructured":"Decitabine and gemcitabine for pancreatic cancer and sarcoma \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02959164?term=Decitabine&draw=2&rank=32 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1190","unstructured":"Testing a new anti-cancer drug combination, entinostat and ZEN003694, for advanced and refractory solid tumors and lymphomas \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05053971 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1195","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115638_b1200","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1200\/JCO.2022.40.16_suppl.4158","article-title":"Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma","volume":"40","author":"Safyan","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b1205","unstructured":"Safety and tolerance of epigenetic and immunomodulating drugs combined with chemotherapeutics in patients suffering from advanced pancreatic cancer \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04257448?term=Romidepsin&draw=2&rank=97 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1210","unstructured":"Guadecitabine and durvalumab in treating patients with advanced liver, pancreatic, bile duct, or gallbladder cancer \u2013 Full Text View \u2013 ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03257761 (accessed March 30, 2023)."},{"key":"10.1016\/j.addr.2025.115638_b1215","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cllc.2023.01.013","article-title":"Mocetinostat in combination with durvalumab for patients with advanced NSCLC: results from a phase I\/II study","volume":"24","author":"Johnson","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.addr.2025.115638_b1220","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1039\/D1NA00682G","article-title":"The Yin and Yang of epigenetics in the field of nanoparticles","volume":"4","author":"Musolino","year":"2022","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.addr.2025.115638_b1225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-019-0709-y","article-title":"Novel prodrugs of decitabine with greater metabolic stability and less toxicity","volume":"11","author":"Hattori","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.addr.2025.115638_b1230","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/cbic.202000138","article-title":"Nitroreductase-mediated release of inhibitors of lysine-specific demethylase 1 (LSD1) from prodrugs in transfected acute myeloid leukaemia cells","volume":"21","author":"Herrlinger","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.addr.2025.115638_b1235","first-page":"4714","article-title":"Design of BET inhibitor bottlebrush prodrugs with superior efficacy and devoid of systemic toxicities","volume":"143","author":"Vohidov","year":"2022","journal-title":"PMC"},{"key":"10.1016\/j.addr.2025.115638_b1240","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1515\/hsz-2018-0451","article-title":"The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation","volume":"400","author":"Vasiljeva","year":"2019","journal-title":"Biol. Chem."},{"key":"10.1016\/j.addr.2025.115638_b1245","doi-asserted-by":"crossref","first-page":"808","DOI":"10.7150\/thno.13826","article-title":"Synthesis and preclinical evaluation of a highly improved anticancer prodrug activated by histone deacetylases and cathepsin L","volume":"6","author":"Ueki","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2025.115638_b1250","article-title":"Perspectives on materials: reality and potential of epigenetic drug nano-delivery","volume":"502","author":"Zhang","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.addr.2025.115638_b1255","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1016\/j.apsb.2023.05.018","article-title":"Current research trends of nanomedicines","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2025.115638_b1260","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23679","article-title":"Mutuality of epigenetic and nanoparticles: two sides of a coin","volume":"10","author":"Sanei","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2025.115638_b1265","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13346-023-01415-7","article-title":"Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management","volume":"14","author":"Abhang","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2025.115638_b1270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120659","article-title":"Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery","volume":"602","author":"Tang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115638_b1275","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111523","article-title":"Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes","volume":"199","author":"Farooq","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2025.115638_b1280","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/10717544.2021.1927246","article-title":"Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy","volume":"28","author":"Lu","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2025.115638_b1285","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.3390\/cancers14184474","article-title":"Enhanced antitumoral activity of encapsulated BET inhibitors when combined with PARP inhibitors for the treatment of triple-negative breast and ovarian cancers","volume":"14","author":"Juan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b1290","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902926","article-title":"Targeting super-enhancers via nanoparticle-facilitated BRD4 and CDK7 inhibitors synergistically suppresses pancreatic ductal adenocarcinoma","volume":"7","author":"Huang","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2025.115638_b1295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/polym13020250","article-title":"QbD Enabled azacitidine loaded liposomal nanoformulation and its in vitro evaluation","volume":"13","author":"Kesharwani","year":"2021","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.addr.2025.115638_b1300","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12951-021-01197-5","article-title":"Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators","volume":"19","author":"Sun","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2025.115638_b1305","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202210895","article-title":"A Bimetallic metal-organic-framework-based biomimetic nanoplatform enhances anti-leukemia immunity via synchronizing DNA demethylation and RNA hypermethylation","volume":"35","author":"Song","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2025.115638_b1310","article-title":"Perspectives on materials: reality and potential of epigenetic drug nano-delivery","volume":"502","author":"Zhang","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.addr.2025.115638_b1315","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1021\/acs.molpharmaceut.0c00294","article-title":"Hyaluronidase coated molecular envelope technology nanoparticles enhance drug absorption via the subcutaneous route","volume":"17","author":"Soundararajan","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2025.115638_b1320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107887","article-title":"Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders","volume":"153","author":"Ibrahim","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.addr.2025.115638_b1325","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.drudis.2021.11.011","article-title":"An updated review of folate-functionalized nanocarriers: A promising ligand in cancer","volume":"27","author":"Ebrahimnejad","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2025.115638_b1330","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.2147\/IJN.S208649","article-title":"Folate-mediated and pH-responsive chidamide-bound micelles encapsulating photosensitizers for tumor-targeting photodynamic therapy","volume":"14","author":"Ma","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2025.115638_b1335","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.omtn.2020.08.024","article-title":"EpCAM-targeted 3WJ RNA nanoparticle harboring delta-5-desaturase siRNA inhibited lung tumor formation via DGLA peroxidation","volume":"22","author":"Pang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.addr.2025.115638_b1340","article-title":"Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic cancer","volume":"8","author":"Sun","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.addr.2025.115638_b1345","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41598-017-02816-8","article-title":"MicroRNA-34a encapsulated in hyaluronic acid nanoparticles induces epigenetic changes with altered mitochondrial bioenergetics and apoptosis in non-small-cell lung cancer cells","volume":"7","author":"Trivedi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115638_b1350","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejmech.2015.04.014","article-title":"Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids","volume":"96","author":"Sodji","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.addr.2025.115638_b1355","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/092986712798918842","article-title":"Multi-targeted histone deacetylase inhibitors in cancer therapy","volume":"19","author":"Ai","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.addr.2025.115638_b1360","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature14581","article-title":"Glypican-1 identifies cancer exosomes and detects early pancreatic cancer","volume":"523","author":"Melo","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115638_b1365","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1477-7819-11-219","article-title":"Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma","volume":"11","author":"Que","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b1370","first-page":"91","article-title":"CPA4 is a promising diagnostic serum biomarker for pancreatic cancer","volume":"6","author":"Sun","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.addr.2025.115638_b1375","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-020-1809-z","article-title":"Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer","volume":"18","author":"Zhang","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.addr.2025.115638_b1380","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123059","article-title":"Understanding the clinical impact of MUC5AC expression on pancreatic ductal adenocarcinoma","volume":"13","author":"Manne","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:40:36Z","timestamp":1778946036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":276,"alternative-id":["S0169409X25001231"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115638","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115638"}}